Company profile: Terns Pharmaceuticals

1.1 - Company Overview

Terns Pharmaceuticals

Headquarter: United States

Founded: 20XX🔒

Employees: 100-500🔒

🌐 Website

Company description

Provider of biopharmaceutical drug discovery and development targeting NASH, obesity, and chronic myeloid leukemia, with a pipeline including TERN-501 (THRβ agonist) and liver-distributed TERN-101 (FXR agonist) for NASH; TERN-701 (allosteric BCR-ABL inhibitor) for CML; TERN-601 (oral GLP-1 agonist) and TERN-800 (GIP modulators, IND-enabling in 2024) for obesity; and TERN-201 (selective VAP-1 inhibitor) for NASH.

Products and services

TERN-101: A liver-distributed farnesoid X receptor agonist architected for NASH, targeting nonalcoholic steatohepatitis with a focus on safety and efficacy
TERN-501: A selective, high metabolic stability thyroid hormone receptor beta agonist engineered to treat NASH with minimal cardiotoxicity risks
TERN-701: An allosteric BCR-ABL tyrosine kinase inhibitor crafted for chronic myeloid leukemia, offering a novel approach to treatment

Key contacts

🔒

Financial details

🔒

1.2 - Competitors and similar companies to Terns Pharmaceuticals

Corpak MedSystems

HQ: United States Website

Description: Provider of enteral feeding and bedside location medical devices, developing, manufacturing, and marketing premium-branded solutions. Portfolio includes the CORTRAK* 2 Enteral Access System for real-time feeding tube placement; MIC-KEY* low-profile G, GJ, and J feeding tubes; the MIC-KEY* Over-the-Wire stoma measuring device; and MIC* PEG kits. Holds a leading position in adult long-term nasogastric feeding tubes.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Corpak MedSystems company profile →

Spirus Medical

HQ: United States Website

Description: Provider of advanced care medical devices for the gastrointestinal and cardiovascular markets, offering a product portfolio that includes the Endo-Ease Discovery and Dexterity Steerable Introducer.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Spirus Medical company profile →

VectivBio

HQ: Switzerland Website

Description: Provider of clinical-stage biotechnology solutions developing transformational medicines for serious rare diseases. Offerings include LINZESS (linaclotide) for IBS-C and CIC; apraglutide, an investigational once-weekly GLP-2 analog for SBS-IF; CNP-104, a potential treatment for primary biliary cholangitis; and IW-3300, a GC-C agonist in development for visceral pain conditions including IC/BPS and endometriosis.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full VectivBio company profile →

Entero Therapeutics

HQ: United States Website

Description: Provider of biopharmaceutical therapies for gastrointestinal diseases, including Latiglutenase, a recombinant digestive enzyme adjunct to a gluten-free diet for celiac disease; Adrulipase, a recombinant lipase to enable digestion of fats and nutrients in exocrine pancreatic insufficiency; and Capeserod, a selective 5-HT4 receptor partial agonist being developed for gastroparesis and other gastrointestinal indications.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Entero Therapeutics company profile →

Meritage Pharma

HQ: United States Website

Description: Provider of prescription products for gastrointestinal and atopic diseases, offering budesonide-based therapies, including an oral budesonide suspension and budesonide API used in treatments for pediatric asthma, allergic rhinitis, and Crohn's disease.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Meritage Pharma company profile →

🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒

🔒 View all strategic buyers with complete profiles

Start Free Trial →

2.2 - Strategic buyer groups for Terns Pharmaceuticals

🔒

Buyer group 1: ████████ ████████

●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔒

Buyer group 2: ████████ ████████

●● companies

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔒

Buyer group 3: ████████ ████████

●● companies

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔓 Unlock all detailed buyer group breakdowns with complete company profiles

Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Terns Pharmaceuticals

Buyout Funds
50+ funds

🔒

🔒

🔒

🔒

🔒 🇺🇸 Top US buyout funds investing in Terns Pharmaceuticals's sector and industry vertical
View Funds →
🔒 🇪🇺 Top Europe buyout funds in Terns Pharmaceuticals's sector and industry vertical
View Funds →

2.2 - Growth funds investing in similar companies to Terns Pharmaceuticals

Growth Equity Funds
40+ funds

🔒

🔒

🔒

🔒

🔒 🇺🇸 Top US growth equity funds investing in Terns Pharmaceuticals's sector and industry vertical
View Funds →
🔒 🇪🇺 Top Europe growth equity funds investing in Terns Pharmaceuticals's sector and industry vertical
View Funds →

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Terns Pharmaceuticals

4.2 - Public trading comparable groups for Terns Pharmaceuticals

🔒

Comparable group 1: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔒

Comparable group 2: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔒

Comparable group 3: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Terns Pharmaceuticals

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA

🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Terns Pharmaceuticals

What does Terns Pharmaceuticals do?

Terns Pharmaceuticals is a provider of biopharmaceutical drug discovery and development targeting NASH, obesity, and chronic myeloid leukemia, with a pipeline including TERN-501 (THRβ agonist) and liver-distributed TERN-101 (FXR agonist) for NASH; TERN-701 (allosteric BCR-ABL inhibitor) for CML; TERN-601 (oral GLP-1 agonist) and TERN-800 (GIP modulators, IND-enabling in 2024) for obesity; and TERN-201 (selective VAP-1 inhibitor) for NASH.

Who are Terns Pharmaceuticals's competitors?

Terns Pharmaceuticals's competitors and similar companies include Corpak MedSystems, Spirus Medical, VectivBio, Entero Therapeutics, and Meritage Pharma.

Where is Terns Pharmaceuticals headquartered?

Terns Pharmaceuticals is headquartered in United States.

How many employees does Terns Pharmaceuticals have?

Terns Pharmaceuticals has 1,000 employees 🔒.

When was Terns Pharmaceuticals founded?

Terns Pharmaceuticals was founded in 2010 🔒.

What sector and industry vertical is Terns Pharmaceuticals in?

Terns Pharmaceuticals is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Terns Pharmaceuticals

Who are the top strategic acquirers in Terns Pharmaceuticals's sector and industry

Top strategic M&A buyers and acquirers in Terns Pharmaceuticals's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Terns Pharmaceuticals?

Top strategic M&A buyers groups and sectors for Terns Pharmaceuticals include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Terns Pharmaceuticals's sector and industry vertical

Which are the top PE firms investing in Terns Pharmaceuticals's sector and industry vertical?

Top PE firms investing in Terns Pharmaceuticals's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Terns Pharmaceuticals's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Terns Pharmaceuticals's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Terns Pharmaceuticals's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Terns Pharmaceuticals include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Terns Pharmaceuticals's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Terns Pharmaceuticals?

The key public trading comparables and valuation benchmarks for Terns Pharmaceuticals include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Terns Pharmaceuticals for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Terns Pharmaceuticals with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Terns Pharmaceuticals's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Terns Pharmaceuticals with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Terns Pharmaceuticals's' sector and industry vertical?

Access recent funding rounds and capital raises in Terns Pharmaceuticals's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Terns Pharmaceuticals

Start Free Trial Book a Demo